Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium

@article{Triggle2017MetforminIN,
  title={Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium},
  author={Chris R. Triggle and Hong Ding},
  journal={Acta Physiologica},
  year={2017},
  volume={219}
}
Metformin, a synthetic dimethyl biguanide, has been in clinical use for over 55 years, and today is considered the first‐choice drug for the treatment of type 2 diabetes used by an estimated 125 million people worldwide. Metformin is orally effective, not metabolized, excreted unchanged by the kidney, relatively free of side effects and well tolerated by the majority of patients. Of importance is that the United Kingdom Prospective Diabetes Study 20‐year study of type 2 diabetics, completed in… Expand
Metformin - a new approach.
TLDR
The benefits of using metformin in the treatment of various diseases are presented, including diabetes, cancer, and other diseases. Expand
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects?
TLDR
Aim of this review is to assess metformin’s beneficial effects on endothelial dysfunction in T2DM, which could preempt development of atherosclerosis. Expand
Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function
TLDR
The role and molecular mechanisms by which metformin acts through VSMCs to protect CVD are provided, including AS, restenosis, and pulmonary hypertension. Expand
An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis.
TLDR
The findings confirm that metformin should constitute first line therapy of T2DM subjects; however, more comprehensive methodical studies are required to discover the full potential of this drug. Expand
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
TLDR
Regardless of glycemic improvement, combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile in patients with type 2 diabetes without advanced atherosclerosis. Expand
Metformin, Macrophage Dysfunction and Atherosclerosis
TLDR
Macrophages play an important role in a variety of diseases, and improving macrophage dysfunction may be an important mechanism for metformin to expand its pleiotropic pharmacological profile. Expand
The Effects of Pycnogenol® as Add‐on Drug to Metformin Therapy in Diabetic Rats
TLDR
Both used agents, PYC and MET, showed improvement of blood glucose levels, vascular reactivity, left ventricular hypertrophy, expression of AMPK, glucose transporter 4 (GLUT4) and calcium/calmodulin‐dependent protein kinase II (CaMKII) in left ventricle of the hearts, however, the combination of these interventions has failed to possess higher efficacy. Expand
Impact of currently used anti-diabetic drugs on myoendothelial communication.
TLDR
This review compares metformin with SGLT2 inhibitors and the data supporting their protective effects on the endothelium and shows great promise for type 2 diabetes patients. Expand
Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing
TLDR
The epidemiological data linking metformin to ARD prevention is summarized, the deeply studied mechanisms of action explaining its antihyperglycemic effect and the putative mechanisms supporting its anti-ageing properties are dissected, and it is hypothesized that the molecular observations obtained in different models with met formin could be indirectly mediated by its effect on gut flora. Expand
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
TLDR
Results uncover how DPP4 inhibition induces insulin sensitization in the vascular wall and suggest that cotreatment with insulin may be therapeutic for patients with cardiometabolic disease and reveal the detrimental effects of insulin on vascular redox state and endothelial function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 145 REFERENCES
Metformin: an old but still the best treatment for type 2 diabetes
TLDR
The role of metformin in the treatment of patients with type 2 diabetes is reviewed, its potential role for a variety of insulin resistant and pre-diabetic states, obesity, metabolic abnormalities associated with HIV disease, gestational diabetes, cancer, and neuroprotection are discussed. Expand
Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium
TLDR
Critically evaluate the data from studies that have investigated the pharmacokinetic properties and the cellular and clinical basis for the oral hypoglycaemic, insulin-sensitising and vascular protective effects of metformin. Expand
Cellular and molecular mechanisms of metformin: an overview.
TLDR
Emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D. Expand
Metformin—mode of action and clinical implications for diabetes and cancer
TLDR
The updated understanding of the antigluconeogenic action of met formin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer are discussed. Expand
Cardiovascular impact of drugs used in the treatment of diabetes
TLDR
A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes, and the evidence for their cardiovascular benefits and risks is addressed. Expand
Clinical Pharmacokinetics of Metformin
TLDR
The effect of structural variants of OCTs and other cation transporters on the pharmacokinetics of metformin appears small and the subsequent effects on clinical response are limited, however, intersubject differences in the levels of expression of OCT1 and OCT3 in the liver are very large and may contribute more to the variations in the hepatic uptake and clinical effect of metforms. Expand
Molecular mechanism of action of metformin: old or new insights?
TLDR
An improvement in understanding of metformin’s molecular targets is likely to enable target-based identification of second-generation drugs with similar properties, a development that has been impossible up to now. Expand
Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat.
TLDR
The results suggest that metformin may be decreasing arterial pressure in the SHR, at least in part, by attenuating the agonist-stimulated [Ca2+]i response in SHR vascular smooth muscle cells. Expand
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
TLDR
The data indicate that OCT1 is important for metformin therapeutic action and that genetic variation in OCT1 may contribute to variation in response to the drug. Expand
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.
TLDR
It is concluded that the drug's pharmacological effects are mediated, at least in part, through a time-dependent, self-limiting inhibition of the respiratory chain that restrains hepatic gluconeogenesis while increasing glucose utilization in peripheral tissues. Expand
...
1
2
3
4
5
...